Association between Tumor Necrosis Factor-α and Disease Progression in Patients with Multiple Sclerosis
- 15 August 1991
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 325 (7) , 467-472
- https://doi.org/10.1056/nejm199108153250704
Abstract
Cachectin, or tumor necrosis factor-α (TNF-α), is a principal mediator of the inflammatory response and may be important in the pathogenesis and progression of multiple sclerosis, an inflammatory disease of the central nervous system.Keywords
This publication has 42 references indexed in Scilit:
- The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosisThe Lancet, 1991
- Improvement in sensitivity of enzyme‐linked immunosorbent assay for tumour necrosis factorImmunology & Cell Biology, 1990
- Role of tumor necrosis factor alpha (cachectin) in experimental and clinical bacterial meningitisThe Pediatric Infectious Disease Journal, 1989
- Correlation of interleukin-1β and cachectin concentrations in cerebrospinal fluid and outcome from bacterial meningitisThe Journal of Pediatrics, 1989
- Detection of Circulating Tumor Necrosis Factor after Endotoxin AdministrationNew England Journal of Medicine, 1988
- Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation.The Journal of Experimental Medicine, 1988
- Rating neurologic impairment in multiple sclerosisNeurology, 1983
- New diagnostic criteria for multiple sclerosis: Guidelines for research protocolsAnnals of Neurology, 1983
- Intensive Immunosuppression in Progressive Multiple SclerosisNew England Journal of Medicine, 1983
- HISTOCOMPATIBILITY DETERMINANTS IN MULTIPLE SCLEROSIS, WITH SPECIAL REFERENCE TO CLINICAL COURSEThe Lancet, 1973